Provided by Tiger Fintech (Singapore) Pte. Ltd.

89Bio, Inc.

6.06
+0.17002.89%
Post-market: 6.120.0600+0.99%19:10 EDT
Volume:1.02M
Turnover:6.09M
Market Cap:884.66M
PE:-1.73
High:6.11
Open:5.85
Low:5.76
Close:5.89
Loading ...

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

Zacks
·
11 Apr

VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe

Zacks
·
08 Apr

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

Zacks
·
08 Apr

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

Zacks
·
03 Apr

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?

Zacks
·
02 Apr

FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda

Zacks
·
28 Mar

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Zacks
·
25 Mar

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Zacks
·
22 Mar

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Zacks
·
22 Mar

Analysts Offer Insights on Healthcare Companies: 89bio (ETNB), Gain Therapeutics (GANX) and Boston Scientific (BSX)

TIPRANKS
·
20 Mar

Goldman Sachs Initiates Coverage on 89bio With Neutral Rating, $11 Price Target

MT Newswires Live
·
14 Mar

89bio Initiated at Neutral by Goldman Sachs

Dow Jones
·
14 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx

Reuters
·
13 Mar

Citi says SMid biotechs alternative to large caps as it starts coverage

Investing.com
·
13 Mar

89Bio Shares up 2% After Citigroup Initiates Coverage With 'Buy' Rating

THOMSON REUTERS
·
13 Mar

89Bio Shares up 3.6% Premarket After Citigroup Initiates Coverage With 'Buy' Rating

THOMSON REUTERS
·
13 Mar

BUZZ-Citi initiates coverage on 89bio with 'buy' rating on potential for MASH therapy

Reuters
·
13 Mar

Citigroup Initiates 89bio Inc at Buy With $25 Price Target

MT Newswires Live
·
13 Mar

BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty

Reuters
·
13 Mar

Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?

Zacks
·
06 Mar